Aniruddha Agarwal1, Rupesh Agrawal2,3,4,5, Dhananjay Raje6, Ilaria Testi5, Sarakshi Mahajan7, Dinesh Visva Gunasekeran2,3, Kanika Aggarwal6, Somasheila I Murthy8,9, Mark Westcott5,6, Soon-Phaik Chee2,4,10,11, Peter Mccluskey12, Su Ling Ho3, Stephen Teoh3, Luca Cimino13, Jyotirmay Biswas14, Shishir Narain15, Manisha Agarwal16, Padmamalini Mahendradas17, Moncef Khairallah18, Nicholas Jones19, Ilknur Tugal-Tutkun20, Kalpana Babu21, Soumayava Basu22, Ester Carreño23, Richard Lee5, Hassan Al-Dhibi24, Bahram Bodaghi25, Alessandro Invernizzi26, Debra A Goldstein27, Carl P Herbort28, Talin Barisani-Asenbauer29, Julio J González-López30, Sofia Androudi31, Reema Bansal1, Bruttendu Moharana1, Simona Degli Esposti5, Anastasia Tasiopoulou5, Sengal Nadarajah5, Mamta Agarwal14, Sharanya Abraham14, Ruchi Vala17, Ramandeep Singh1, Aman Sharma32, Kusum Sharma33, Manfred Zierhut34, Onn Min Kon35, Emmett T Cunningham36, John H Kempen37,38, Quan Dong Nguyen8, Carlos Pavesio5, Vishali Gupta1. 1. Advanced Eye Centre, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. 2. Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. 3. National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore. 4. Department of Ophthalmology, Singapore Eye Research Institute, Singapore, Singapore. 5. Department of Ophthalmology, Moorfields Eye Hospital, NHS Foundation Trust, London, UK. 6. Department of Statistics, UCL Institute of Ophthalmology, London, UK. 7. Department of Ophthalmology, MDS Bioanalytics, India. 8. Byres Eye Institute, Stanford University, Palo Alto, California, USA. 9. Department of Ophthalmology, Tej Kohli Cornea Institute, LV Prasad Eye Institute, Kallam Anji Reddy Campus, Hyderabad, India. 10. Singapore National Eye Centre, Singapore, Singapore. 11. Department of Ophthalmology & Visual Sciences Academic Clinical Program, Duke-NUS Medical School, Singapore City, Singapore. 12. Department of Clinical Ophthalmology & Eye Health, Central Clinical School, Save Sight Institute, the University of Sydney, Sydney, Australia. 13. Ocular Immunology Unit, Azienda USL IRCCS, Reggio, Italy. 14. Department of Ophthalmology, Sankara Nethralaya, Chennai, India. 15. Department of Ophthalmology, Shroff Eye Centre, New Delhi, India. 16. Department of Ophthalmology, Dr Shroff's Charity Eye Hospital Daryaganj, New Delhi, India. 17. Department of Uveitis and Ocular Immunology, Narayana Nethralaya, Bangalore, India. 18. Department of Ophthalmology, Fattouma Bourguiba University Hospital, Faculty of Medicine, University of Monastir, Tunisia. 19. Department of Ophthalmology, University of Manchester, Manchester, UK. 20. Istanbul Faculty of Medicine, Department of Ophthalmology, Istanbul University, Istanbul, Turkey. 21. Prabha Eye Clinic & Research Centre, Vittala International Institute of Ophthalmology, Bangalore, India. 22. Department of Ophthalmology, LV Prasad Eye Institute, Bhubaneswar, India. 23. Department of Ophthalmology, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain. 24. Department of Ophthalmology, King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia. 25. Department of Ophthalmology, DHU SightRestore, Sorbonne University, Paris, France. 26. Eye Clinic, Department of Biomedical and Clinical Science "L. Sacco", Luigi Sacco Hospital, University of Milan, Milan, Italy. 27. Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. 28. Department of Ophthalmology, Centre for Ophthalmic Specialised Care & University of Lausanne, Lausanne, Switzerland. 29. The Centre for Ocular Inflammation and Infection (OCUVAC), Laura Bassi Centre of Expertise Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria. 30. Department of Ophthalmology, Ramón Y Cajal University Hospital, Madrid, Spain. 31. Department of Ophthalmology, University of Thessaly, Thessaly, Greece. 32. Department of Rheumatology, PGIMER, Chandigarh, India. 33. Department of Microbiology, PGIMER, Chandigarh, India. 34. Centre of Ophthalmology, Department of Ophthalmology, University of Tuebingen, Tuebingen, Germany. 35. Chest and Allergy Clinic, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK. 36. UCSF School of Medicine, The Francis I. Proctor Foundation, San Francisco, California, USA. 37. Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA. 38. MCM Eye Unit, MyungSung Christian Medical Center and MyungSung Medical School, Addis Ababa, Ethiopia.
Abstract
Purpose: To report the clinical findings, anatomical features, and treatment outcomes in subjects with ocular tuberculosis (OTB) at 24 months in the Collaborative Ocular Tuberculosis Study (COTS)-1. Methods: Of the 945 subjects included in COTS-1, those who completed a 24-month follow-up after completion of treatment were included. The main outcome measure was a number of patients with treatment failure (TF). Results: 228 subjects (120 males; mean age of 42.82 ± 14.73 years) were included. Most common phenotype of uveitis was posterior (n = 81; 35.53%), and panuveitis (n = 76; 33.33%). Fifty-two patients (22.81%) had TF. On univariable analysis, odds of high TF was observed with bilaterality (OR: 3.46, p = .003), vitreous haze (OR: 2.14, p = .018), and use of immunosuppressive therapies (OR: 5.45, p = .003). However, only bilaterality was significant in the multiple regression model (OR: 2.84; p = .02).Conclusions: Majority of subjects (>75%) achieved cure in the COTS-1 at 24-month follow-up. The concept of "cure" may be a valuable clinical endpoint in trials for OTB.
Purpose: To report the clinical findings, anatomical features, and treatment outcomes in subjects with ocular tuberculosis (OTB) at 24 months in the Collaborative Ocular Tuberculosis Study (COTS)-1. Methods: Of the 945 subjects included in COTS-1, those who completed a 24-month follow-up after completion of treatment were included. The main outcome measure was a number of patients with treatment failure (TF). Results: 228 subjects (120 males; mean age of 42.82 ± 14.73 years) were included. Most common phenotype of uveitis was posterior (n = 81; 35.53%), and panuveitis (n = 76; 33.33%). Fifty-two patients (22.81%) had TF. On univariable analysis, odds of high TF was observed with bilaterality (OR: 3.46, p = .003), vitreous haze (OR: 2.14, p = .018), and use of immunosuppressive therapies (OR: 5.45, p = .003). However, only bilaterality was significant in the multiple regression model (OR: 2.84; p = .02).Conclusions: Majority of subjects (>75%) achieved cure in the COTS-1 at 24-month follow-up. The concept of "cure" may be a valuable clinical endpoint in trials for OTB.